TrialsgrambetaRCTs are beautiful

MURANO

2018

Venetoclax + Rituximab in Relapsed/Refractory CLL

In 389 patients with relapsed or refractory chronic lymphocytic leukaemia, fixed-duration venetoclax + rituximab for two years improved progression-free survival compared with bendamustine + rituximab.

Result

Efficacy: Progression-free survivalHR 0.17

Below 1 favours fixed-duration venetoclax + rituximab for two years, above 1 favours bendamustine + rituximab.

Event rates
Absolute difference
48.6 points

The absolute difference is derived from the event rates.

Also reported: 4-yr OS 85.3% vs 66.8% (HR 0.41).

Original publication
Subtopic
Relapsed/refractory CLL
Design
Open-label RCT
Relevance
Important: one of several pillars.
Source
Seymour JF, et al. N Engl J Med. 2018;378(12):1107-1120; Kater AP, et al. J Clin Oncol. 2020;38(34):4042-4054.doi 10.1056/NEJMoa1713976

Discussion & critique

Established fixed-duration, MRD-driven, chemotherapy-free therapy in R/R CLL, a paradigm now extended to first-line treatment (CLL14).